Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) - Bristol Myers Squibb
Bristol Myers Squibb reports on Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with... in Science & Health.
Take A Coffee NEWS Staff··2 min read
Bristol Myers Squibb reported Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL). Take A Coffee NEWS is tracking the story on the Science & Health desk for readers following medicine, public health, research, climate, space, and science policy.
Source
Why it matters
The story belongs in this desk because it may affect readers tracking medicine, public health, research, climate, space, and science policy.